Affiliation:
1. SAĞLIK BİLİMLERİ ÜNİVERSİTESİ, ANKARA DR. ABDURRAHMAN YURTASLAN ONKOLOJİ SAĞLIK UYGULAMA VE ARAŞTIRMA MERKEZİ
2. SAĞLIK BİLİMLERİ ÜNİVERSİTESİ, ANKARA DR. ABDURRAHMAN YURTASLAN ONKOLOJİ SAĞLIK UYGULAMA VE ARAŞTIRMA MERKEZİ, DAHİLİ TIP BİLİMLERİ BÖLÜMÜ, İÇ HASTALIKLARI ANABİLİM DALI, ONKOLOJİ BİLİM DALI
Abstract
Aims: The subtype of lung cancer, known as small cell lung cancer (SCLC), tends to have a highly fatal course, especially in advanced stages. In particular, the overall survival durations further decrease in cases of brain metastases in SCLC. There is increasing evidence for the role of systemic inflammation parameters in predicting cancer prognosis, and they appear likely to become potential target markers for clinical treatments in the future. We aimed to evaluate the systemic inflammation response index (SIRI), a novel inflammatory laboratory marker that could predict long-term survival and serve as a potential target marker for clinical treatment, in patients with de novo brain metastatic small cell lung carcinoma (DNBM SCLC)."
Methods: Clinicopathological features of adult patients diagnosed with DNBM SCLC were recorded from the patient registry of the hospital. Patients without medical records were not included in the study. Investigations were carried out to assess the prognostic effect of the SIRI parameter in predicting the 12-month overall survival (OS12) in DNBM SCLC patients, by determining a cut-off value and conducting appropriate statistical analyses, considering p-values (
Publisher
Journal of Health Sciences and Medicine
Subject
General Earth and Planetary Sciences,General Environmental Science
Reference25 articles.
1. World Health Organization 2019. International agency for research on cancer. Available at: https://www.iarc.who.int/
2. Remon J, Aldea M, Besse B, et al. Small cell lung cancer: a slightly less orphan disease after immunotherapy. Ann Oncol. 2021;32(6);698-709.
3. Thai AA, Solomon BJ, Sequist LV, Gainor JF, Heist RS. Lungcancer. Lancet (London, England). 2021;398(10299);535-554.
4. Thomas A, Pattanayak P, Szabo E, Pinsky P. Characteristics and outcomes of small cell lung cancer detected by CT screening. Chest. 2018;154(6);1284-1290.
5. Riihimäki M, Hemminki A, Fallah M, et al. Metastatic sites and survival in lung cancer. Lungcancer. 2014;86(1);78-84.